The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.

Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD, Bouillon R

Clinical endocrinology1 May 2002Cited by 82 (Europe PMC)

PMID12030918DOI10.1046/j.1365-2265.2002.01255.xPepBankPUB-12030918

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study23

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 infusion alone reactivated GH secretion.
In plain wordsIn men with prolonged critical illness, GHRP‑2 infusion restarted growth hormone release.
Peptide
GHRP-2
Outcome
IncreaseGH secretion with GHRP-2 alone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3 and ALS.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091801
02HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 infusion alone normalized serum IGF-I.
In plain wordsIn men with prolonged critical illness, GHRP‑2 infusion brought blood IGF-I back to normal.
Peptide
GHRP-2
Outcome
IncreaseSerum IGF-I with GHRP-2 alone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3 and ALS.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091802
03HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 infusion alone normalized serum IGFBP-3.
In plain wordsIn men with prolonged critical illness, GHRP‑2 infusion brought blood IGFBP-3 back to normal.
Peptide
GHRP-2
Outcome
IncreaseSerum IGFBP-3 with GHRP-2 alone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3 and ALS.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091803
04HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 infusion alone normalized serum acid-labile subunit (ALS).
In plain wordsIn men with prolonged critical illness, GHRP‑2 infusion brought the blood level of ALS back to normal.
Peptide
GHRP-2
Outcome
IncreaseSerum acid-labile subunit with GHRP-2 alone
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
GHRP-2 infusion reactivated GH secretion and normalized serum IGF-I, IGFBP-3 and ALS.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091804
05HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 alone did not reduce ureagenesis.
In plain wordsIn men with prolonged critical illness, GHRP‑2 alone did not lower urea production.
Peptide
GHRP-2
Outcome
No significant changeUreagenesis with GHRP-2 alone
Study
n = 9
Outcome group
Mitochondrial function · Metabolic and weight
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
Ureagenesis was reduced by GHRP-2 + TRH + GnRH (P = 0.01) and by GHRP-2 + TRH (P = 0.009) but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091805
06HumanRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 alone did not increase serum osteocalcin.
In plain wordsIn men with prolonged critical illness, GHRP‑2 alone did not raise blood osteocalcin, a bone marker.
Peptide
GHRP-2
Outcome
No significant changeSerum osteocalcin with GHRP-2 alone
Study
n = 9
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
Serum OC levels were increased only by GHRP-2 + TRH + GnRH (P = 0.03), with a trend for GHRP-2 + TRH (P = 0.09), but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091806
07HumanRandomized controlled trialOther
In men with prolonged critical illness, serum lactate was increased on day 5 by GHRP‑2 infused alone.
In plain wordsIn men with prolonged critical illness, blood lactate was higher on day 5 after GHRP‑2 infusion alone.
Peptide
GHRP-2
Outcome
IncreaseSerum lactate on day 5 with GHRP-2 alone
Study
n = 9
Outcome group
Adverse events · Metabolic and weight
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091807
08HumanRandomized controlled trialOther
In men with prolonged critical illness, white blood cell count was increased on day 5 by GHRP‑2 infused alone.
In plain wordsIn men with prolonged critical illness, white blood cell count was higher on day 5 after GHRP‑2 infusion alone.
Peptide
GHRP-2
Outcome
IncreaseWhite blood cell count on day 5 with GHRP-2 alone
Study
n = 9
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1 microg/kg/h · infusion · 5 daysAs given in this study (human).
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
Report a problemFND-1203091808

Studies that did not test the peptide alone15

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

09HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH infusion reactivated the GH axis.
In plain wordsIn men with prolonged critical illness, a GHRP‑2 and TRH infusion restarted the growth hormone axis.
Peptide
GHRP-2
Outcome
IncreaseGH axis with GHRP-2 + TRH
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GHRP-2 + TRH infusion reactivated both the GH axis and the thyroid axis
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091809
10HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH infusion reactivated the thyroid axis, with normal T4 and T3 reached within 1 day.
In plain wordsIn men with prolonged critical illness, a GHRP‑2 and TRH infusion restarted the thyroid axis, with normal thyroid hormones within 1 day.
Peptide
GHRP-2
Outcome
IncreaseThyroid axis and T4, T3 with GHRP-2 + TRH
Study
n = 9
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
GHRP-2 + TRH infusion reactivated both the GH axis and the thyroid axis, with normal levels of T4 and T3 reached within 1 day.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091810
11HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH reduced ureagenesis.
In plain wordsIn men with prolonged critical illness, GHRP‑2 with TRH lowered urea production.
Peptide
GHRP-2
Outcome
DecreaseUreagenesis with GHRP-2 + TRH
Study
n = 9
Outcome group
Mitochondrial function · Metabolic and weight
Source sentences
Summary
Ureagenesis was reduced by GHRP-2 + TRH + GnRH (P = 0.01) and by GHRP-2 + TRH (P = 0.009) but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091817
12HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH showed only a trend toward higher serum osteocalcin.
In plain wordsIn men with prolonged critical illness, GHRP‑2 with TRH showed only a trend toward higher blood osteocalcin.
Peptide
GHRP-2
Outcome
No significant changeSerum osteocalcin with GHRP-2 + TRH
Study
n = 9
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum OC levels were increased only by GHRP-2 + TRH + GnRH (P = 0.03), with a trend for GHRP-2 + TRH (P = 0.09), but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091819
13HumanNot a test of GHRP-2 aloneRandomized controlled trialOther
In men with prolonged critical illness, serum lactate was increased on day 5 by GHRP‑2 combined with TRH.
In plain wordsIn men with prolonged critical illness, blood lactate was higher on day 5 after GHRP‑2 combined with TRH.
Peptide
GHRP-2
Outcome
IncreaseSerum lactate on day 5 with GHRP-2 + TRH
Study
n = 9
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091820
14HumanNot a test of GHRP-2 aloneRandomized controlled trialOther
In men with prolonged critical illness, white blood cell count was increased on day 5 by GHRP‑2 combined with TRH.
In plain wordsIn men with prolonged critical illness, white blood cell count was higher on day 5 after GHRP‑2 combined with TRH.
Peptide
GHRP-2
Outcome
IncreaseWhite blood cell count on day 5 with GHRP-2 + TRH
Study
n = 9
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091821
15HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH infusion with GnRH pulses reactivated the GH axis versus placebo.
In plain wordsIn men with prolonged critical illness, GHRP‑2 and TRH with GnRH pulses restarted the growth hormone axis compared with placebo.
Peptide
GHRP-2
Outcome
IncreaseGH axis with GHRP-2 + TRH + GnRH
Study
n = 8
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Only GHRP-2 + TRH infusion combined with GnRH pulses reactivated the GH and TSH axis and at the same time increased pulsatile LH secretion compared to placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091811
16HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH infusion with GnRH pulses reactivated the TSH axis versus placebo.
In plain wordsIn men with prolonged critical illness, GHRP‑2 and TRH with GnRH pulses restarted the thyroid-stimulating hormone axis compared with placebo.
Peptide
GHRP-2
Outcome
IncreaseTSH axis with GHRP-2 + TRH + GnRH
Study
n = 8
Comparator
Placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Only GHRP-2 + TRH infusion combined with GnRH pulses reactivated the GH and TSH axis and at the same time increased pulsatile LH secretion compared to placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091812
17HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH infusion with GnRH pulses increased pulsatile LH secretion versus placebo.
In plain wordsIn men with prolonged critical illness, GHRP‑2 and TRH with GnRH pulses raised LH release compared with placebo.
Peptide
GHRP-2
Outcome
IncreasePulsatile LH secretion with GHRP-2 + TRH + GnRH
Study
n = 8
Comparator
Placebo
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Only GHRP-2 + TRH infusion combined with GnRH pulses reactivated the GH and TSH axis and at the same time increased pulsatile LH secretion compared to placebo.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091813
18HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, only GHRP‑2 + TRH infusion with GnRH pulses increased testosterone significantly, with a peak increase of 312%.
In plain wordsIn men with prolonged critical illness, only GHRP‑2 and TRH with GnRH pulses clearly raised testosterone.
Peptide
GHRP-2
Outcome
IncreaseSerum testosterone with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Peak testosterone increase
312%
GHRP-2 + TRH + GnRH
Source sentences
Summary
Only GnRH pulses together with GHRP-2 + TRH infusion increased testosterone significantly from day 2 (peak increase of + 312%)
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091814
19HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, only GHRP‑2 + TRH infusion with GnRH pulses increased serum E2 by more than 80% from day 1 through day 3.
In plain wordsIn men with prolonged critical illness, only GHRP‑2 and TRH with GnRH pulses raised oestradiol levels in the first days.
Peptide
GHRP-2
Outcome
IncreaseSerum oestradiol with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Measurements
Serum E2 increase
> 80%
GHRP-2 + TRH + GnRH
Source sentences
Summary
Only GnRH pulses together with GHRP-2 + TRH infusion increased testosterone significantly from day 2 (peak increase of + 312%) through day 5 and serum E2 with > 80% from day 1 through day 3 (all P = 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091815
20HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, GHRP‑2 + TRH + GnRH reduced ureagenesis.
In plain wordsIn men with prolonged critical illness, GHRP‑2 with TRH and GnRH lowered urea production.
Peptide
GHRP-2
Outcome
DecreaseUreagenesis with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Mitochondrial function · Metabolic and weight
Source sentences
Summary
Ureagenesis was reduced by GHRP-2 + TRH + GnRH (P = 0.01) and by GHRP-2 + TRH (P = 0.009) but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091816
21HumanNot a test of GHRP-2 aloneRandomized controlled trialEfficacy outcome
In men with prolonged critical illness, serum osteocalcin was increased by GHRP‑2 + TRH + GnRH.
In plain wordsIn men with prolonged critical illness, GHRP‑2 with TRH and GnRH raised blood osteocalcin, a bone marker.
Peptide
GHRP-2
Outcome
IncreaseSerum osteocalcin with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Serum OC levels were increased only by GHRP-2 + TRH + GnRH (P = 0.03), with a trend for GHRP-2 + TRH (P = 0.09), but not by GHRP-2 alone.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091818
22HumanNot a test of GHRP-2 aloneRandomized controlled trialOther
In men with prolonged critical illness, serum lactate was not increased on day 5 by GHRP‑2 + TRH + GnRH.
In plain wordsIn men with prolonged critical illness, blood lactate did not rise on day 5 with GHRP‑2, TRH and GnRH.
Peptide
GHRP-2
Outcome
No significant changeSerum lactate on day 5 with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091822
23HumanNot a test of GHRP-2 aloneRandomized controlled trialOther
In men with prolonged critical illness, white blood cell count was not increased on day 5 by GHRP‑2 + TRH + GnRH.
In plain wordsIn men with prolonged critical illness, white blood cell count did not rise on day 5 with GHRP‑2, TRH and GnRH.
Peptide
GHRP-2
Outcome
No significant changeWhite blood cell count on day 5 with GHRP-2 + TRH + GnRH
Study
n = 8
Outcome group
Inflammation markers · Immune and inflammation
Source sentences
Summary
On day 5, serum lactate levels and WBC count were increased by GHRP-2 infused alone and in combination with TRH but not by GHRP-2 + TRH + GnRH.
1 context sentence(design, population, supporting numbers)
Summary · context
Patients were randomly assigned to 5 days of placebo (n = 7), GHRP-2 (1 microg/kg/h; n = 9), GHRP-2 + TRH infusion (1 + 1 microg/kg/h; n = 9) or pulsatile GnRH (0.1 microg/kg every 90 min) together with GHRP-2 + TRH infusion (n = 8).
In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.
Report a problemFND-1203091823

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.

Summary

Results from this study23

Studies that did not test the peptide alone15

Version history

Subjects

Publication types

MeSH terms